Triptorelin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Triptorelin: From Gonadal Hormone Suppression (GnRH Agonist Therapy) to Hypertrichosis
One-Sentence Summary
Triptorelin is a GnRH (gonadotropin-releasing hormone) agonist that suppresses sex hormones, and it is marketed in Singapore as injectable depot products. The TxGNN model predicts it may be effective for hypertrichosis with a very high score, but there are 0 clinical trials and only 1 publication, a case report that does not support this use. This prediction rests on the model alone, so the evidence is very weak.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.997% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
The Singapore licence records compiled for this report do not include approved indication text, so the original indication is not listed here.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Triptorelin is a GnRH agonist. Continuous stimulation desensitises pituitary GnRH receptors and suppresses LH and FSH, which in turn lowers gonadal sex steroids.
This prediction is not mechanistically convincing. Hypertrichosis is excessive hair growth that is not androgen-dependent. It is often drug-induced (for example by ciclosporin) or congenital. No credible pathway links GnRH agonism to treating it. Suppressing sex hormones would not be expected to reverse it.
The only publication retrieved is a case report of ciclosporin-induced hypertrichosis in a transgender woman who was also taking estradiol and triptorelin. The hypertrichosis was attributed to ciclosporin, and the report shows that it occurred despite androgen suppression. This is not evidence that triptorelin treats the condition. The high TxGNN score is a statistical prediction only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41822646 | 2026 | Case report | Cureus | Generalised hypertrichosis caused by ciclosporin in a 25-year-old transgender woman with psoriasis. She was also on estradiol and triptorelin, so the report shows hypertrichosis arising despite androgen suppression. It does not show a treatment benefit. |
Singapore Market Information
Six valid single-ingredient licences are registered. The first five are listed below, and approved indication text is not available for them.
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN14323P | Pamorelin Powder for Suspension for Injection 3.75 mg per vial | Injection, lyophilised powder for suspension |
| SIN14324P | Pamorelin Powder for Suspension for Injection 11.25 mg per vial | Injection, lyophilised powder for suspension |
| SIN14325P | Pamorelin Powder for Suspension for Injection 22.5 mg per vial | Injection, lyophilised powder for suspension |
| SIN14634P | Diphereline P.R. Powder and Solvent for Suspension for Injection 3.75 mg/vial | Injection, extended-release powder for suspension |
| SIN08697P | Decapeptyl Injection 0.1 mg/ml | Injection |
Safety Considerations
Please refer to the package insert for key warnings and contraindications.
- Disease associations from the knowledge graph (not label text): The TxGNN knowledge graph links triptorelin to the following conditions as potential contraindications. These should be checked against the official label before any use:
- hypertension
- kidney disease
- liver disease
- gallbladder disease
- hyperglycaemia
- diabetes mellitus
- diabetic ketoacidosis
- obesity
- urinary tract obstruction
- spinal cord disease
- pyoureter
- Drug interactions: 100 interactions were identified.
- Major: dolasetron.
- Moderate (examples): antidiabetic agents such as metformin, pioglitazone, glimepiride, acarbose, dapagliflozin, empagliflozin, canagliflozin, alogliptin, saxagliptin, dulaglutide and albiglutide.
- Moderate (others): clarithromycin, famotidine, palonosetron, loperamide, bisacodyl and bowel-preparation agents.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials, a single irrelevant case report, and no plausible mechanism for GnRH agonism to treat hypertrichosis. The high TxGNN score alone does not justify further development for this indication.
To proceed, the following is needed:
- A credible mechanistic hypothesis linking GnRH agonism to the type of hypertrichosis targeted
- Preclinical or clinical data in hypertrichosis patients
- Full package insert warnings and contraindications for triptorelin
Note on other predictions: Among the other predicted indications, precocious puberty (rank 8, TxGNN score 99.89%) has much stronger support. It has several completed Phase 3 trials of triptorelin in central precocious puberty and extensive supporting literature, and the mechanism is consistent. This is most likely a confirmation of existing use rather than true repurposing, and it would warrant a separate evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.